Effector Therapeutics Stock Short Ratio
EFTRWDelisted Stock | USD 0 0.00 0.00% |
EFFECTOR Therapeutics fundamentals help investors to digest information that contributes to EFFECTOR Therapeutics' financial success or failures. It also enables traders to predict the movement of EFFECTOR Pink Sheet. The fundamental analysis module provides a way to measure EFFECTOR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EFFECTOR Therapeutics pink sheet.
EFFECTOR |
EFFECTOR Therapeutics Company Short Ratio Analysis
EFFECTOR Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, EFFECTOR Therapeutics has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
All Next | Launch Module |
EFFECTOR Fundamentals
Return On Equity | -9.47 | |||
Return On Asset | -0.83 | |||
Number Of Shares Shorted | 18.44 K | |||
EBITDA | (33.73 M) | |||
Net Income | (35.81 M) | |||
Total Debt | 19.45 M | |||
Book Value Per Share | 0.21 X | |||
Cash Flow From Operations | (29.55 M) | |||
Earnings Per Share | (0.91) X | |||
Number Of Employees | 14 | |||
Beta | 0.62 | |||
Total Asset | 20.54 M | |||
Retained Earnings | (179.38 M) | |||
Working Capital | (5.96 M) | |||
Net Asset | 20.54 M |
About EFFECTOR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EFFECTOR Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EFFECTOR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EFFECTOR Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |